NEW YORK (GenomeWeb News) – Ligon Discovery today said that it will use its Small Molecule Microarray (SMM) screening platform to discover candidates for Bayer Schering Pharma's drug development programs.
The Cambridge, Mass.-based firm said that its technology works by affixing drug candidates to a slide, enabling it to use cell lysates, instead of "developing a complex assay based on a full understanding of a protein target's functions."
This method allows it to screen every protein in an entire target class or every protein in a disease pathway, the firm said.
"Our partnership with Bayer Schering Pharma provides the opportunity to demonstrate the unique capabilities of SMM, particularly to screen challenging targets and identify unique starting points for drug development," Ligon Discovery CEO Christian Bailey said in a statement.
Financial terms of the agreement were not released.